Twist Bioscience (NASDAQ:TWST) Reaches New 12-Month High – Time to Buy?

Twist Bioscience Corporation (NASDAQ:TWST) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $148.81 and last traded at $149.1050, with a volume of 72068 shares traded. The stock had previously closed at $140.80.

Wall Street Analysts Forecast Growth

Several research firms recently commented on TWST. Piper Sandler raised their price target on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Robert W. Baird upped their price objective on shares of Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. UBS Group set a $89.00 target price on shares of Twist Bioscience in a research report on Monday, June 15th. Leerink Partners set a $110.00 target price on shares of Twist Bioscience in a research note on Thursday, July 16th. Finally, Canaccord Genuity Group boosted their price target on shares of Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $98.30.

Twist Bioscience Price Performance

The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The stock has a market capitalization of $9.44 billion, a price-to-earnings ratio of -67.85 and a beta of 2.14. The stock’s 50 day simple moving average is $101.89 and its 200-day simple moving average is $71.16.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The business had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.33 EPS. On average, analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 14,205 shares of the business’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $89.75, for a total value of $1,274,898.75. Following the completion of the sale, the insider owned 105,141 shares of the company’s stock, valued at $9,436,404.75. The trade was a 11.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paula Green sold 291 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $87.32, for a total value of $25,410.12. Following the sale, the senior vice president owned 120,414 shares of the company’s stock, valued at approximately $10,514,550.48. This trade represents a 0.24% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 151,529 shares of company stock valued at $17,708,772. Corporate insiders own 3.08% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Large investors have recently made changes to their positions in the business. Quarry LP acquired a new position in shares of Twist Bioscience during the third quarter worth approximately $28,000. Western Wealth Management LLC acquired a new stake in shares of Twist Bioscience in the first quarter worth $31,000. Strs Ohio acquired a new stake in shares of Twist Bioscience in the first quarter worth $33,000. Strategic Advocates LLC increased its position in Twist Bioscience by 562.7% during the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after acquiring an additional 906 shares during the period. Finally, SBI Securities Co. Ltd. increased its position in Twist Bioscience by 68.9% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after acquiring an additional 571 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.